

Life Sciences Industry Insight



Bay Area, CA


Market gains momentum as tenant demand starts to accelerate

VC funding is ramping up, surpassing \$2B for the first time in three quarters

VC funding reached \$2.5B in Q3, indicating that VC is starting to rebound. The majority of investment was allocated towards early-stage companies. Of the top five deals across the U.S., the Bay Area was home to three of the largest VC rounds. In fact, the largest VC round in this quarter was Neuralink in Fremont which raised \$280M. In addition to VC, economic fundamentals such as employment and job postings are starting to increase, showing initial signs of recovery which will eventually translate into leasing volume.

\$280 M \$255 M Neuralink (Series D) \$215 M MAPS Public Benefit (Series A) Second Framework Second Framework \$255 M Cellares (Series C) \$200 M Genesis Therapeutics (Series B)

Life sciences employment and establishments



Life sciences venture capital investment activity



Source: Crunchbase

Leasing volume remains steady with 76.2% of deals being under 30,000 s.f.


Leasing volume closed the quarter at 441,00 s.f.

Bay Area wide, leasing volume was at 441,000 s.f., with 47.2% of leasing concentrated in the North County submarket cluster. The largest completed deal was Pliant Therapeutics signing 101,000 s.f. at 331 Oyster Point in South San Francisco. DRA/BRV's Marina Village project in Alameda accounted for nearly a quarter of the region's leasing, led by an expansion by lota for 54,000 s.f. Other notable transactions include Vaxcyte's 37,000 s.f. lease assignment with Codexis at 825 Industrial Rd in San Carlos. Vaxcyte now will occupy 40.7% of the building. Smaller deals under 30,000 s.f. accounted for 76.2% of leases. The trend towards smaller spaces reflect current requirements with 69.1% of active tenants looking for lab spaces 30,000 s.f. or less. However, the Bay Area is starting to see larger requirements emerging, showing positive signs for future leasing activity.

Vacancy rate rises to 16.2%


Vacancy grew 270 basis points as 720,000 s.f. delivered vacant. Going into the fourth quarter, 2.0M s.f. of unleased space is expected to deliver. This quarter witnessed -224,000 s.f. of net absorption, where the biggest contributors include Perfect Day's 64,700 s.f. moveout at 740 Heinz St and 52,000 s.f. at 3000 Bridge from Altos Lab's restructuring around Redwood LIFE. The largest move-in was 10x Genomics's new development with 164,000 s.f. at 1701 Springdale Ave in Pleasanton. Despite an upshift in vacancy, total asking rents remained stable quarter-over-quarter. Average asking rents fell 3.8% off their peak in 2022 to \$6.66 NNN.

Completed lease transactions and leases signed



Source: JLL

Vacancy and NNN rent trends



Source: JLL

Notable lease transactions								
Company	Address or Property	Submarket	Size (s.f.)	Date signed	Туре			
Pliant Therapeutics	331 Oyster Point	South San Francisco	100,904	9/18/2023	New			
lota Biosciences	400 Wind River Way	Alameda	53,545	9/20/2023	Expansion			
Vaxcyte	825 Industrial Rd	San Carlos	36,593	9/1/2023	New			
Centrillion Technologies	2500 Faber Pl	Palo Alto	32,820	7/25/2023	Renewal			
Walking Fish Therapeutics	450 E Jamie Ct	South San Francisco	29,745	7/1/2023	New			

Development activity stabilizes


The quarter witness 894,000 s.f. of deliveries

The total under-development supply narrowed to 8.5M, down from its 10M s.f. peak in Q4 2022. Two projects broke ground this quarter: Beacon Capital & Menlo Equities' 241,000 s.f. at 405 Industrial Rd in San Carlos and Trammell Crow's 220,000 s.f. at 200 Twin Dolphin Dr in Redwood Shores. The largest projects delivered were Tishman Speyer's Mission Rock 300,000 s.f. Building B in San Francisco, Graymark Capital's 230,000 s.f. lab space at 150 Industrial Rd in San Carlos, and 10x Genomic's 163,500 s.f. lab space at 1701 Springdale Ave in Pleasanton. The lab pipeline will lessen as fewer projects are moving forward. Out of the total pipeline, only 14.4% is pre-leased. Rents are likely to experience downward pressure with the amount of new development and sublease spaces coming on the market.

Sublease availability climbs to 5%

570,000 s.f. of subleases hit the market in the third quarter, raising sublease availability 120 basis points quarter-over-quarter to 5% or 2.3M s.f. This is the highest rate observed in the Bay Area in nearly two decades, with 65% of the added sublease available supply coming from Mission Bay. While some companies made available sublease space, others chose to negotiate lease terminations. Atreca who previously put their space for sublease terminated their 100,000 s.f. lease at Alexandria's Center for Life Sciences in San Carlos. To remain competitive, developers are offering more concessions and building out spec suites.

Development pipeline



Source: JLL Research

Availability Trends



Top Upcoming Deliveries								
Expected Delivery	Name	Address	City	Size (s.f.)	Owner	Туре		
Q4 2023	Berkeley Commons	600 Addison St 601 Bancroft St	Berkeley	538,826	Lane Partners	Ground-Up		
Q4 2023	Vantage	494 Forbes Blvd Bldg A/B	South San Francisco	342,000	Healthpeak	Ground-Up		
Q4 2023	651 Gateway	651 Gateway	South San Francisco	325,215	ARE	Conversion		
Q4 2023	751 Gateway	751 Gateway	South San Francisco	321,000	ARE	Ground-Up		

Q3 2023 Statistics

			Total net	YTD total net	YTD total net			Average	YTD	Under
	Class	Inventory (s.f.)	absorption		absorption (%	Direct		direct acking	Completions	
		, ,	(s.f.)	(s.f.)		vacancy (%)	vacancy (%)	rent (\$ p.s.f.)	(s.f.)	(s.f.)
Bay Area	Totals	35,873,380	-223,997	-23,605	-0.1%	11.8%	16.2%	\$6.90	3,760,180	8,525,930
			Total net		YTD total net	Direct	Total	Average		Under
	Class	Inventory (s.f.)	absorption		absorption (%		vacancy (%)	direct asking	Completions	
	-	470.000	(s.f.)	(s.f.)	of stock)			rent (\$ p.s.f.)	(s.f.)	(s.f.)
Belmont	Totals	176,000	0	0		100.0%	100.0%			0
Foster City	Totals	1,399,787	43,958	43,958		0.0%	4.0%			0
Redwood Shores	Totals	787,789	-59,323	40,511		12.9%	12.9%			51,678
San Carlos	Totals	1,178,862	-4,800	-4,708		20.2%	22.0%			902,139
San Mateo	Totals	181,222	23,729	23,729		21.4%	24.4%			680,050
Central County Brisbane	Totals Totals	3,723,660 976,147	3,564 -38,877	103,490 -65,558		14.9% 5.7%	17.1% 14.5%		•	1,633,867 566,661
Burlingame/Millbrae	Totals	108,318	-30,011	300		7.0%	14.5%			1,103,939
Daly City	Totals	432,000	26,439	314,074		35.5%	35.5%			1,103,939
San Bruno	Totals	432,000	20,433	0		0.0%	0.0%			0
South San Francisco	Totals	11,463,504	-96,669	-417,978		8.5%	12.9%			2,908,566
North County	Totals	12,979,969	-109,107	-169,162		9.2%	13.8%			4,579,166
Menlo Park	Totals	970,522	-47,414	-94,544		10.6%	16.3%			
Redwood City	Totals	1,552,819	-7,913	-257,948		16.0%	21.6%			755,000
South County	Totals	2,523,341	-55,327	-352,492		13.9%	19.6%			755,000
Mid-Peninsula	Totals	19,226,970	-160,870	-418,164		10.9%	15.2%			6,968,033
		, ,	,	·				·		
	-1		Total net		YTD total net	Direct	Total	Average	YTD	Under
	Class	Inventory (s.f.)	absorption		absorption (%		vacancy (%)	direct asking	Completions	
Usersand	T. 4.1.	1 210 176	(s.f.)	(s.f.)	of stock)			rent (\$ p.s.f.)	(s.f.)	(s.f.)
Hayward	Totals	1,218,176	-39,478	87,567	7.2%	13.6%	25.3%	\$4.27	51,845	0
880 Corridor Alameda-North	Totals	1,218,176	- 39,478	87,567	7.2% -2.5%	13.6% 7.5%	25.3%	\$4.27 \$5.85	51,845	0
Alameda-North	Totals Totals	710,523 1,505,406	37,261	-17,886 53,879	3.6%	9.8%	10.9% 9.8%	\$5.18	48,850	0
Berkeley	Totals	893,060	-48,635	-99,879	-11.2%	7.3%	18.8%	\$7.40	22,043	538,826
Emeryville	Totals	3,114,480	-68,248	220,250	7.1%	13.0%	23.2%	\$6.92	624,689	349,698
Richmond	Totals	1,221,752	00,210	0	0.0%	0.6%	0.6%	\$3.00	02 1,000	0 13,030
Oakland Metro	Totals	7,445,221	-79,622	156,364	2.1%	9.1%	15.1%	\$6.91	695,582	888,524
Livermore	Totals	389,768	0	0	0.0%	0.0%	0.0%		0	0
Pleasanton	Totals	782,329	130,548	112,631	14.4%	7.4%	10.2%	\$2.67	163,500	0
San Ramon	Totals	96,535	0	0		0.0%	0.0%	\$0.00	0	0
South 680 Corridor	Totals	1,268,632	130,548	112,631	8.9%	4.6%	6.3%	\$2.67	163,500	0
East Bay	Totals	9,932,029	11,448	356,562	3.6%	9.1%	15.2%	\$6.49	910,927	888,524
			Tatalmat	VTD total mat	VTD total mot			A	VTD	Llondou
	Class	Inventory (s.f.)	Total net absorption		YTD total net absorption (%	Direct	Total	Average direct asking	YTD Completions I	Under Dovolopment
	Class	inventory (s.i.)	(s.f.)	(s.f.)	of stock)	vacancy (%)	vacancy (%)	rent (\$ p.s.f.)	(s.f.)	(s.f.)
Fremont	Totals	823,604	0	106,067	12.9%	4.4%	10.2%	\$4.25	0	0
Milpitas	Totals	102,189	0	-48,947	-47.9%	56.5%	56.5%	\$3.75	0	0
Mountain View	Totals	288,870	0	0	0.0%	23.7%	23.7%	\$6.25	68,558	0
Newark	Totals	319,951	0	-31,659	-9.9%	43.6%	43.6%	\$5.12	0	0
North San Jose	Totals	469,267	0	41,351	8.8%	3.6%	5.7%	\$2.65	68,252	0
Palo Alto	Totals	1,323,539	0	473	0.0%	6.3%	6.7%	\$7.86	46,504	138,577
Sunnyvale	Totals	64,788	0	0	0.0%	73.3%	73.3%	\$3.90	0	0
Suburban	Totals	3,392,208	0	67,285	2.0%	13.3%	15.1%	\$5.81	183,314	138,577
Silicon Valley	Totals	3,392,208	0	67,285	2.0%	13.3%	15.1%	\$5.81	183,314	138,577
			Total net	VTD total mat	VTD total mot			A	VTD	l lood au
	Class	Inventory (s.f.)	absorption		YTD total net absorption (%	Direct	Total	Average direct asking	YTD Completions I	Under
	Class	inventory (s.i.)	(s.f.)	(s.f.)	of stock)	vacancy (%)	vacancy (%)	rent (\$ p.s.f.)	(s.f.)	(s.f.)
Dogpatch / Pier 70	Totals	0	(3.1.)	(3.1.)	0.0%	0.0%	0.0%	\$0.00	(3.1.)	(3.1.)
Mission Bay/China Basin	Totals	3,151,993	-74,575	-29,288	-0.9%	22.4%	24.8%	\$7.14	1,050,370	530,796
Showplace Square	Totals	170,180	0	0	0.0%	39.1%	39.1%	\$6.00	0	0
Non-CBD	Totals	3,322,173	-74,575	-29,288	-0.9%	23.2%	25.5%	\$7.08	1,050,370	530,796
San Francisco	Totals	3,322,173	-74,575	-29,288	-0.9%	23.2%	25.5%	\$7.08	1,050,370	530,796
		, , ,	, -	., , , , ,				, .,,	, ,	,



JLL Life Sciences Group

Crystal Fok

Research Analyst +1 650 480 2226 Crystal.Fok@ill.com

Grant Dettmer

Senior Managing Director +1 650 480 2138 Grant.Dettmer@jll.com Lic # 02014572

Allison Hoffmann

Executive Vice President +1 971 645 6127 Allison.Hoffmann@jll.com Lic # 02075868

Emmanuel Enabulele

Associate +1 650 480 2130 Emmanuel.Enabulele@jll.com Lic# 02195583

Grant Yeatman

Managing Director +1 510 465 9406 <u>Grant.Yeatman@jll.com</u> Lic # 01972905

Gabi Lessey

Transaction Manager +1 650 833 8423 Gabrielle.Lessey@jll.com Lic # 02157473

Scott W. Miller

Executive Managing Director +1 650 480 2199 ScottW.Miller@jll.com Lic # 01457617

Cole Smith

Executive Vice President +1 650 480 2230 Cole.Smith@jll.com Lic # 01948128

Alexander Quinn

Director of Research, Northern CA +1 415 395 4924 <u>Alexander.Quinn@jll.com</u>

About JLL

JLL (NYSE: JLL) is a leading professional services firm that specializes in real estate and investment management. JLL shapes the future of real estate for a better world by using the most advanced technology to create rewarding opportunities, amazing spaces and sustainable real estate solutions for our clients, our people and our communities. JLL is a Fortune 500 company with annual revenue of \$18.0 billion, operations in over 80 countries and a global workforce of more than 94,000 as of March 31, 2020. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit jll.com.

About JLL Research

JLL's research team delivers intelligence, analysis and insight through market-leading reports and services that illuminate today's commercial real estate dynamics and identify tomorrow's challenges and opportunities. Our more than 400 global research professionals track and analyze economic and property trends and forecast future conditions in over 60 countries, producing unrivalled local and global perspectives. Our research and expertise, fueled by real-time information and innovative thinking around the world, creates a competitive advantage for our clients and drives successful strategies and optimal real estate decisions.

© 2023 Jones Lang LaSalle IP, Inc. All rights reserved. The information contained in this document is proprietary to Jones Lang LaSalle and shall be used solely for the purposes of evaluating this proposal. All such documentation and information remains the property of Jones Lang LaSalle and shall be kept confidential. Reproduction of any part of this document is authorized only to the extent necessary for its evaluation. It is not to be shown to any third party without the prior written authorization of Jones Lang LaSalle. All information contained herein is from sources deemed reliable; however, no representation or warranty is made as to the accuracy thereof.